The clinical and economic impact of chronic venous insufficiency-associated lymphedema and the prevalence of persistent edema after venous intervention
Restricted accessResearch articleFirst published online June, 2024
The clinical and economic impact of chronic venous insufficiency-associated lymphedema and the prevalence of persistent edema after venous intervention
To determine the demographics, outcomes, and healthcare utilization of patients with chronic venous insufficiency-associated lymphedema (CVI-LED) and the prevalence of lymphedema-specific therapy use after venous intervention.
Methods
The IBM MarketScan Commercial and Medicare Claims Databases were examined for patients with CVI-LED. Patient demographics and the use of lymphedema-specific therapy before and after venous intervention were collected.
Results
Of 85,601 LED patients identified, 8,406 also had a diagnosis of CVI. In the CVI-LED group, 1051 underwent endovenous ablation or venous stent placement. The use of lymphedema-specific therapy before and after venous intervention was 52% and 39%, respectively (p < .05). The mean time of initiation of LED-specific therapy following venous intervention was 265 days after ablation and 347 days after stent placement.
Conclusion
Treating venous hypertension improves certain venous-related signs and symptoms of CVI. However, a significant proportion of patients have persistent edema which may reflect underlying, sub-optimally treated LED.
BunkeNBrownKBerganJ. Phlebolymphemeda: usually unrecognized, often poorly treated. Perspect Vasc Surg Endovasc Ther2009; 21: 65–68. DOI: 10.1177/1531003509337155.
2.
LeeBBAndradeMAntignaniPL, et al.Diagnosis and treatment of primary lymphedema. Consensus document of the International Union of Phlebology (IUP)-2013. Int Angiol2013; 32: 541–574.
3.
FarrowW. Phlebolymphedema-a common underdiagnosed and undertreated problem in the wound care clinic. J Am Col Certif Wound Spec2010; 2: 14–23. DOI: 10.1016/j.jcws.2010.04.004.
4.
SantlerBGoergeT. Chronic venous insufficiency - a review of pathophysiology, diagnosis, and treatment. J Dtsch Dermatol Ges2017; 15: 538–556. DOI: 10.1111/ddg.13242.
5.
MichelCCWoodcockTECurryFRE. Understanding and extending the Starling principle. Acta Anaesthesiol Scand2020; 64: 1032–1037. DOI: 10.1111/aas.13603.
6.
MortimerPS. The pathophysiology of lymphedema. Cancer1998; 83: 2798–2802.
7.
LevickJRMichelCC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res2010; 87: 198–210. DOI: 10.1093/cvr/cvq062.
8.
SonAO'DonnellTFJr.IzhakoffJ, et al.Lymphedema-associated comorbidities and treatment gap. J Vasc Surg Venous Lymphat Disord2019; 7: 724–730. DOI: 10.1016/j.jvsv.2019.02.015.
9.
LermanMGaeblerJAHoyS, et al.Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. J Vasc Surg2019; 69: 571–580. DOI: 10.1016/j.jvs.2018.04.028.
KolluriRLugliMVillalbaL, et al.An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med2022; 27: 63–72. DOI: 10.1177/1358863x211028298.
12.
SimkaMMajewskiE. The social and economic burden of venous leg ulcers: focus on the role of micronized purified flavonoid fraction adjuvant therapy. Am J Clin Dermatol2003; 4: 573–581. DOI: 10.2165/00128071-200304080-00007.
13.
MaHO'DonnellTFJr.RosenNA, et al.The real cost of treating venous ulcers in a contemporary vascular practice. J Vasc Surg Venous Lymphat Disord2014; 2: 355–361. DOI: 10.1016/j.jvsv.2014.04.006.
DissemondJAssenheimerBBültemannA, et al.Compression therapy in patients with venous leg ulcers. J Dtsch Dermatol Ges2016; 14: 1072–1087. DOI: 10.1111/ddg.13091.
17.
MotykieGDCapriniJAArcelusJI, et al.Evaluation of therapeutic compression stockings in the treatment of chronic venous insufficiency. Dermatol Surg1999; 25: 116–120. DOI: 10.1046/j.1524-4725.1999.08095.x.
18.
RajuSDarceyRNeglénP. Unexpected major role for venous stenting in deep reflux disease. J Vasc Surg2010; 51: 401–408. DOI: 10.1016/j.jvs.2009.08.032.
19.
ParavastuSCHorneMDoddPD. Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins. Cochrane Database Syst Rev2016; 11: Cd010878. DOI: 10.1002/14651858.CD010878.pub2.
20.
WarrenAGBrorsonHBorudLJ, et al.Lymphedema: a comprehensive review. Ann Plast Surg2007; 59: 464–472. DOI: 10.1097/01.sap.0000257149.42922.7e.
21.
GreeneAKGossJA. Diagnosis and staging of lymphedema. Semin Plast Surg2018; 32: 12–16. DOI: 10.1055/s-0038-1635117.
22.
RasmussenJCZhuBMorrowJR, et al.Degradation of lymphatic anatomy and function in early venous insufficiency. J Vasc Surg Venous Lymphat Disord2021; 9: 720–730.e2. DOI: 10.1016/j.jvsv.2020.09.007.
23.
KayıranODe La CruzCTaneK, et al.Lymphedema: from diagnosis to treatment. Turk J Surg2017; 33: 51–57. DOI: 10.5152/turkjsurg.2017.3870.
24.
SchererKKhilnaniN. Evaluation and management of patients with leg swelling: therapeutic options for venous disease and lymphedema. Semin Intervent Radiol2021; 38: 189–193. DOI: 10.1055/s-0041-1727162.
25.
RajuS. Best management options for chronic iliac vein stenosis and occlusion. J Vasc Surg2013; 57: 1163–1169. DOI: 10.1016/j.jvs.2012.11.084.
26.
TaradajJRosińczukJDymarekR, et al.Comparison of efficacy of the intermittent pneumatic compression with a high- and low-pressure application in reducing the lower limbs phlebolymphedema. Therapeut Clin Risk Manag2015; 11: 1545–1554. DOI: 10.2147/tcrm.S92121.
